Henry Jemil Esber
Corporate Officer/Principal bei Esber D&D Consulting
Profil
Henry Jemil Esber was the founder of Bio-Quant, Inc. founded in 2000 where he held the title of Chief Business Officer & Senior Vice President.
Dr. Esber is also the founder of Biosignature Diagnostics, Inc., Advanced Drug Delivery, Inc. Dr. Esber's current job is as Principal at Esber D&D Consulting since 2005.
Dr. Esber's former jobs include Director & Executive Vice President at Apricus Biosciences, Inc. from 2009 to 2013, Director at Galectin Therapeutics, Inc. from 2006 to 2009, Director at Innovus Pharmaceuticals, Inc. from 2011 to 2019, Director at Avanyx Therapeutics, Inc. from 2009 to 2010, Director at Primedica Corp, Director at Charles River Laboratories Edinburgh Ltd.
from 2000 to 2005, Director at Mason Laboratories, Inc., Independent Director at Boston Therapeutics, Inc. from 2012 to 2016, Director at rEVO Biologics, Inc., Independent Director at BioXyTran, Inc., Director at BioXyTran, Inc., Vice President at TSI Corp, and Vice President at Primedica Cambridge, Inc. Dr. Esber's education includes an undergraduate degree from The College of William & Mary, a graduate degree from The University of North Carolina at Charlotte, and a doctorate degree from West Virginia University School of Medicine.
Aktive Positionen von Henry Jemil Esber
| Unternehmen | Position | Beginn |
|---|---|---|
| Esber D&D Consulting | Corporate Officer/Principal | 01.01.2005 |
Ehemalige bekannte Positionen von Henry Jemil Esber
| Unternehmen | Position | Ende |
|---|---|---|
| INNOVUS PHARMACEUTICALS INC | Chairman | - |
Oxygen Therapy, Inc.
 Oxygen Therapy, Inc. Pharmaceuticals: MajorHealth Technology Oxygen Therapy, Inc. is an early stage pharmaceutical company, which engages in the development, manufacture, and commercialization of an innovative platform of oxygen therapeutic treatments for hypoxic conditions and necrosis prevention. Its product pipeline includes OTI-629, an anti-necrosis drug; and OTI-1011, a resuscitative agent for wound healing applications. The company was founded by David Platt on May 20, 2016 and is headquartered Newton, MA. | Director/Board Member | 03.08.2018 |
| NANOMIX CORPORATION | Director/Board Member | 11.09.2016 |
Apricus Biosciences, Inc.
 Apricus Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Apricus Biosciences, Inc. is a biopharmaceutical company, which engages in the development and commercialization of product candidates in the areas of specialty urology and rheumatology. Its products include Vitaros and Femprox. The company was founded in 1987 and is headquartered in San Diego, CA. | Director/Board Member | 04.01.2013 |
Avanyx Therapeutics, Inc.
 Avanyx Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Avanyx Therapeutics, Inc. engages in the development, manufacture and marketing of therapeutic drugs with a focus on glyco-pathology, a specialized field involving understanding the importance of Glycoproteins in biochemistry and progression of diseases. The company is headquartered in Newton, MA | Director/Board Member | 30.11.2010 |
Ausbildung von Henry Jemil Esber
| The College of William & Mary | Undergraduate Degree |
| The University of North Carolina at Charlotte | Graduate Degree |
| West Virginia University School of Medicine | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| GALECTIN THERAPEUTICS INC. | Health Technology |
| BIOXYTRAN, INC. | Health Technology |
| Private Unternehmen | 16 |
|---|---|
Apricus Biosciences, Inc.
Apricus Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Apricus Biosciences, Inc. is a biopharmaceutical company, which engages in the development and commercialization of product candidates in the areas of specialty urology and rheumatology. Its products include Vitaros and Femprox. The company was founded in 1987 and is headquartered in San Diego, CA. | Health Technology |
Innovus Pharmaceuticals, Inc.
 Innovus Pharmaceuticals, Inc. Pharmaceuticals: OtherHealth Technology Innovus Pharmaceuticals, Inc. engages in the commercialization, licensing, and development of non-prescription medicine, and consumer care products for health and vitality, and respiratory diseases. Its products focuses in six main categories, including sexual health, pain management, general muscle health, respiratory, sleep, and diabetic care. The company was founded on January 15, 1959 and is headquartered in Englewood, CO. | Health Technology |
Avanyx Therapeutics, Inc.
Avanyx Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Avanyx Therapeutics, Inc. engages in the development, manufacture and marketing of therapeutic drugs with a focus on glyco-pathology, a specialized field involving understanding the importance of Glycoproteins in biochemistry and progression of diseases. The company is headquartered in Newton, MA | Health Technology |
| TSI Corp | Commercial Services |
Primedica Cambridge, Inc.
 Primedica Cambridge, Inc. Medical/Nursing ServicesHealth Services Primedica Cambridge, Inc. is based in Cambridge, MA. Primedica Cambridge, Inc. provides testing services to the medical industry. The company was founded by Michael Lovell. Primedica Cambridge was acquired by rEVO Biologics, Inc. on July 17, 1995 for $2.40 million. | Health Services |
Primedica Corp
 Primedica Corp Pharmaceuticals: MajorHealth Technology Part of Charles River Laboratories International, Inc., Primedica Corp develops and produces pharmaceutical products for the biopharmaceutical industry. The private company is based in Worcester, MA. Primedica was acquired by Charles River Laboratories, Inc. from rEVO Biologics, Inc. on February 27, 2001 for $42.50 million. | Health Technology |
Charles River Laboratories Edinburgh Ltd.
 Charles River Laboratories Edinburgh Ltd. Pharmaceuticals: MajorHealth Technology Charles River Laboratories Edinburgh Ltd. provides drug development services. The company is headquartered in Tranent, the United Kingdom. | Health Technology |
Bio-Quant, Inc.
 Bio-Quant, Inc. Medical SpecialtiesHealth Technology Bio-Quant, Inc. develops natural product components for treatment of cancer and diseases. The company is headquartered in San Diego, CA. | Health Technology |
| Esber D&D Consulting | |
| Biosignature Diagnostics, Inc. | |
| Advanced Drug Delivery, Inc. | |
Mason Laboratories, Inc.
 Mason Laboratories, Inc. BiotechnologyHealth Technology Mason Laboratories, Inc. develops and produces recombinant proteins for therapeutic and diagnostic uses. The private company is based in Worcester, MA and ultimately controlled by the Government of France. | Health Technology |
Boston Therapeutics, Inc.
 Boston Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Boston Therapeutics, Inc. is a pharmaceutical company, which engages in the development, manufacture, and commercialization of novel compounds based on complex carbohydrate chemistry. Its products are designed to help manage blood sugar, treat pre-diabetes, and diabetes related pathologies. Its drug candidates comprises of BTI320, BTI-410, and IPOXYN. The company was founded by David Platt and Kenneth A. Tassey Jr. on August 24, 2009 and is headquartered in Lawrence, MA. | Health Technology |
rEVO Biologics, Inc.
 rEVO Biologics, Inc. BiotechnologyHealth Technology rEVO Biologics, Inc. engages in the development and commercialization of specialty therapeutics to address unmet medical needs in patients with rare, life-threatening conditions. Its products include ATryn, which prevents blood clots during and after surgery and childbirth for patients with hereditary antithrombin deficiency. The company was founded in February 1993 and is headquartered in Framingham, MA. | Health Technology |
Oxygen Therapy, Inc.
Oxygen Therapy, Inc. Pharmaceuticals: MajorHealth Technology Oxygen Therapy, Inc. is an early stage pharmaceutical company, which engages in the development, manufacture, and commercialization of an innovative platform of oxygen therapeutic treatments for hypoxic conditions and necrosis prevention. Its product pipeline includes OTI-629, an anti-necrosis drug; and OTI-1011, a resuscitative agent for wound healing applications. The company was founded by David Platt on May 20, 2016 and is headquartered Newton, MA. | Health Technology |
BioXyTran, Inc. /Old/
 BioXyTran, Inc. /Old/ Pharmaceuticals: MajorHealth Technology BioXyTran, Inc. operates as a biopharmaceutical company. The firm focuses on the development and commercialization of treatments to prevent catastrophic brain damage resulting from hypoxic conditions following brain stroke. The company was founded in 2017 and is headquartered in Newton, MA. | Health Technology |
